clinical trial · NCT01008813
Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)
French National Agency for Research on AIDS and Viral Hepatitis·phase2·completed·n = 306
HIV Infectionsadjuvanted A(H1N1)v influenza vaccinenon-adjuvanted A(H1N1)v influenza vaccine
brief summary
A 1-year multicenter, randomized, single-blinded, phase II trial, stratified on HAART. The purpose of this trial is to evaluate the immunogenicity and safety of a A(H1N1)French National Agency for Research on AIDS and Viral Hepatitis influenza vaccine, administered with or without adjuvant, in HIV-infected patients after one or two injections.
started
Oct 1, 2009
primary completion
Feb 1, 2010
completion
Dec 1, 2010
last updated
Apr 7, 2026
official title
A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol